The Coronavirus (CoV) {#Sec1}
=====================

CoVs are enveloped positive sense RNA viruses that have four genera: alphacoronavirus, betacoronavirus, gammacoronavirus and deltacoronavirus (Fehr and Perlman [@CR26]). CoV are spherical with a diameter of 125 nm (Zhao et al. [@CR59]). The viral genome is 30 kb long with a 5′ cap and 3′ poly-A tail. Up to 20 kb of the viral genome codes non-structural proteins, whereas 10 kb codes for structural proteins. The latter include the viral spike (S), envelop (E), membrane (M) and nucleocapsid (N) (Brian and Baric [@CR12]). The spike proteins project form the envelop surface of the virus giving the virus a solar corona-like appearance, and hence the name corona (Beniac et al. [@CR10]). Spikes are composed of two proteins, termed S1 and S2, and these S1/S2 form homotrimers that are heavily N-linked glycosylated; specific regions of the S1 protein (termed Receptor Binding Domains, RBD). These engage the ACE2 receptors expressed on cell surface receptors to enter host cells (Delmas and Laude [@CR17]). After binding with the host cell surface receptor, the S1/S2 containing spike is cleaved by a furin-like protease to generate two polypeptides. S1 contains the receptor-binding domain (RDB) and S2 forms the spike protein stalk (Luytjes et al. [@CR41]; Abraham et al. [@CR1]). Human CoV belonging to the betacoronavirus family cause respiratory and enteric diseases and include human CoV 229E, OC43, NL63, HKU1, severe acute respiratory syndrome (SARS) and the Middle East Respiratory Syndrome (MERS). All can lead to pulmonary disease with significant associated morbidities and mortality rates. The present outbreak of the CoV referenced as SARS-CoV-2 was reported from Wuhan, China in late December 2019. Later, on February 11, the World Health Organization (WHO) named the viral strain SARS-CoV-2 and declared its spread a pandemic. The disease that results from SARS-CoV-2 infection is called COVID-19 (reviewed recently by Rothan and Byrareddy [@CR50]). SARS-CoV-2 belongs to the clade of SARS-CoVs that include bat-derived viruses (Hu et al. [@CR31]; Luk et al. [@CR40]). Like SARS-CoV, SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE-2) receptor to infect host cells that includes, but are not limited to, airway epithelium and parenchyma cells, vascular endothelial cells, kidney and small intestinal cells (Baig et al. [@CR8]). The S1-S2 cleavage site of the spike of SARS-CoV-2 has a unique 12 nucleotide insertion sequence with three predicted O-linked glycans; whereas most spikes of other HCoV have N-linked glycans (Andersen et al. [@CR2]). The function of the O-linked glycan contains a predicted 'mucin-like domain' with a glycan shield that can promote immune escape (Bagdonaite and Wandall [@CR7]). While awaiting further confirmation, SARS-CoV-2 has up to 96% similarity in genomic sequence with CoVs isolated from horseshoe bats found in caves within the Hunnan China. The bat SARS-CoV is named RaTG13 which was isolated from the Chinese rufous horseshoe bat (Rhinolophus sinicus). All support the idea that the bat is the natural viral reservoir (Zhou et al. [@CR60]).

Clinical Manifestations and Laboratory Diagnosis of SARS-CoV-2 Infection {#Sec2}
========================================================================

SARS CoV-2 infection leads to significant disease now termed COVID-19. Symptoms of COVID-19 include fever, cough, diarrhea, and fatigue progressing to severe respiratory impairments and the acute respiratory distress syndrome (ARDS). A diagnosis of COVID-19 disease is made by molecular-based (real-time reverse transcriptase-polymerase chain reaction) viral nucleic acid detection and is supported by panels of hematological (reduced numbers of CD45+, CD3+, CD4+, CD8+, CD19+ and CD16/56+ cells, abnormal liver and metabolic functions. These are coincident with upper and lower respiratory tract disease sometimes progressing to ARDS (Fu et al. [@CR28]; Pan et al. [@CR48]). However, such signs and symptoms now appear to be simply a part of the constellation of presenting clinical features for COVID-19. Indeed, recent studies affirm that neurologic disease manifestations are a significant part of an already large number of disease manifestations (Asadi-Pooya and Simani [@CR6]). It is known that invasion of the central nervous system (CNS by the human CoV (HCoV) occurs shortly after infection and through immune escape. The virus enters the CNS and infects neurons creating a range of disease-related consequences (McGavern and Kang [@CR45]; Desforges et al. [@CR19]). This includes more widespread neurodegeneration (Li et al. [@CR38]; Desforges et al. [@CR21]; Wu et al. [@CR56]). CNS disease manifestations commonly appears directly after infection, late in the disease course or following recovery (Conde Cardona et al. [@CR16]). These observations are not only seen for SARS-CoV-2 but are mirrored by all betacoronaviruses (Desforges et al. [@CR21]). Such findings were affirmed during the SARS-CoV pandemic of 2002--2003. During this time autopsy examinations demonstrated HCoV particles in infected human brain tissues. CNS invasion of zoonotic viruses offers no potential evolutionary advantage. This is underscored by the fact that immune viral clearance is limited for neuronal viral infections. Indeed, antiviral cytolytic T cells demonstrate reduced surveillance activities in the brain (Koyuncu et al. [@CR35]). In a recent case study, meningoencephalitis was seen as a major clinical manifestation of COVID-19. Notably this was recorded without respiratory symptoms (Duong et al. [@CR24]). In this report, a person with a history of type-2 diabetes presented with a low-grade fever of 100.5 ° F, headache, stiff neck, photophobia, seizure without respiratory distress. Anti-epileptic therapy was started for the management of viral meningitis. The clinical progression demonstrated rapid clinical deterioration with disorientation and hallucinations. SARS-CoV-2 detection tests were positive, and she was treated with hydroxychloroquine with improvement in symptoms during a clinical course of 5 days following admission to hospital. In a second case, a young man in his twenties presented total anosmia and ageusia with high suspicion of SARS-CoV-2 infection (Stripp and Sondergaard [@CR53]).

CoV and Animal Models of CNS Infection {#Sec3}
======================================

The localization of the virus in brain tissues was studied in mice infected with SARS-CoV34 and MERS-CoV13 (Netland et al. [@CR46]). The brainstem was the target source of viral infection (McCray et al. [@CR44]; Netland et al. [@CR46]; Li et al. [@CR37]). As cardio-respiratory impairments could reflect brainstem dysfunction it may, in part, be responsible for ARDS as frequently occurs as a cause of COVID-19 mortality among SARS-CoV-2 infected patients (Netland et al. [@CR46]; Dube et al. [@CR23]; Li et al. [@CR39]). This reflects findings in other neurotropic CoVs that included mouse hepatitis virus, porcine hemagglutinating encephalitis virus, and feline CoV (Greig et al. [@CR29]; Arbour et al. [@CR4]; Foley et al. [@CR27]). While HCoV infections are restricted to the upper and lower respiratory systems, it is clear that virus can cross epithelial barriers to reach the periphery and then be transmitted to other organs including the CNS by hematogenous spread (Gu et al. [@CR30]; Nicholls et al. [@CR47]; Desforges et al. [@CR19], [@CR20]). Most of the human CoV strains including 229E, OC43 and SARS productively infect mononuclear phagocytes (MP). It has been suggested that the virus manipulates innate immune responses intrinsic to this cell lineage and subsequently serves as a reservoir for the virus. MP infection of alveolar macrophages can trigger innate immune activation and release of pro-inflammatory secretory factors that may also, in part, by responsible for lung tissue injury and ARDS.

CNS Viral Entry and Neurological Disease Manifestations {#Sec4}
=======================================================

HCoV enters the CNS from blood and peripheral organs then spreads to the brain (Collins [@CR15]; Nicholls et al. [@CR47]; Desforges et al. [@CR18]). HCoV may also enter CNS through neuronal dissemination, in which the virus initially infects peripheral neurons and from there, using host cell machinery, infects CNS neurons (Koyuncu et al. [@CR35]) (Fig. [1](#Fig1){ref-type="fig"}). Using the murine model of HCoV infection, it was shown that SARS and OC43 were able to enter the olfactory bulb after exposure by the nasal route; then using olfactory pathways invades the CNS then specifically the brain stem (Netland et al. [@CR46]; Dube et al. [@CR23]). The fact that COVID-19 patients have impaired olfactory function supports this view (Eliezer et al. [@CR25]). Furthermore, the CT scan and MRI analysis of this patient revealed 'bilateral inflammatory obstruction of the olfactory clefts' (Eliezer et al. [@CR25]). SARS-CoV-2 may also play a role in impaired olfactory function due to its structural and genomic similarities to SARS-CoV, as well as its shared mechanism of entrance into host cells by use of the ACE-2 receptor. Xydakis et al., reported anosmia alone or in combination of parageusia is frequently encountered in COVID-19 patients (Xydakis et al. [@CR57]). "The American Academy of Otolaryngology---Head and Neck Surgery" and "The British Association of Otorhinolaryngology" recommends adding these symptoms in the list of primary screening for COVID-19 (Xydakis et al. [@CR57]). As the impaired ability to smell and test are a common manifestation of respiratory neurotropic viral invasion of the olfactory system, we suspect there is a possibility that SARS-CoV-2 can infect the olfactory system and may enter the CNS using the olfactory pathway. A retrospective study substantiates this, wherein, 36.4% of patients out of 214 confirmed cases of SARS-CoV-2 have been documented to present with varying degree of neurological manifestations that include skeletal muscle injury, delirium and acute cerebrovascular disease (Mao et al. [@CR43]) (Fig. [2](#Fig2){ref-type="fig"}). Another study from China during the early days of the pandemic, reported neurological manifestations including confusion and headache (Chen et al. [@CR14]). This report supports results of the previous studies that showed the presence of high titers of HCoV antibodies found in the cerebrospinal fluid of multiple sclerosis (MS) patients as compared with controls, although both groups had similar levels of serum antibody (Salmi et al. [@CR51]). This is further supported by the finding of the presence of HCoV RNA in post-mortem brain tissues from MS patients (Stewart et al. [@CR52]). The findings suggest that MS patients are at higher risk of HCoV neuroinvasion.Fig. 1The neurovirulence of SARS-CoV-2. Increasing data has now provided evidence that SARS-C0V-2 is both neurotropic and neurovirulent. The virus invades the CNS soon after infection and gains access into the CSF and to brain subregions that include the brain stem and cortex. After crossing the blood-brain barrier (BBB) virus can replicate in microglia and neurons with collateral damage to the barrier. An inflammatory cascade is set into motion that includes ongoing collateral damage and secondary seizures, delirium and stroke. A key finding that is the requirements of the ACE2 cell entry receptor. The CoV spike glycoprotein, by which SARS-CoV-2 binds to cell membranes. The expression of this receptor in neurons and endothelial cells outlines the virus neuroinvasive potential. It is possible that both respiratory and neural failures are linked to brain stem damage and as such both direct infection and indirect inflammatory mechanisms are likely both operative. Differential host immune-mediated responses may determine outcomes. Disease models are surely needed to investigate potential neurological complications and to explore mechanisms of alternative immune-mediated pathogenicity and developmental therapiesFig. 2Neurological signs and symptoms occur as a result of SARS-COV-2 infection. These are in addition to life threatening ARDS. These include, but are not limited to, headache, dizziness, myalgia and fatigue, ARDS (a primary part of the disease complex, brain stem (respiratory and cardiac) impairments, primary cardiac disease, anosmia, an inflammatory encephalitis, delirium and cognitive impairments, stroke, seizures, spinal cord injuries and the Guillain-Barre syndrome. All are associated with SARS-CoV-2 infections

It is of interest to examine the data on studies performed using the mouse hepatitis virus (MHV), an enveloped RNA virus that belongs to the coronaviridae family. The MHV produces acute infection of the CNS that gradually gets controlled by cytolytic CD8+ T cells. However, MHV has the capacity to immune escape leading to the establishment of a chronic CNS infection and progressive demyelination in the brain, which is a hallmark of MS (Wu et al. [@CR55]; Bergmann et al. [@CR11]). As SARS-CoV-2, belongs to same family as MHV, it may also be responsible for demyelination in the brain and lead to conditions similar to that noted in MS patients. It is important to remember that MS patients are treated with corticosteroids. They thus remain in an immune-compromised state and fall in a high-risk group of getting infected with SARS-CoV-2, which warrants extra careful surveillance of MS patients during this ongoing global pandemic.

Guillain-Barré Syndrome {#Sec5}
=======================

Guillain-Barré Syndrome (GBS) is a rare autoimmune disorder that presents with bilateral weaknesses and neuromuscular paralysis (Willison et al. [@CR54]). Among the different phenotypes of GBS "acute inflammatory demyelinating polyradiculoneuropathy" is the most common in which auto-antibodies attack the myelin membranes, whereas in "acute motor axonal neuropathy, auto-antibodies attack the axonal membranes of the peripheral nerves (Leonhard et al. [@CR36]). Most of the patients have a history of suffering from a variety of infectious diseases within 4--6 weeks prior to the development of symptoms with GBS. The infectious agents that have so far been reported include *Campylobacter jejuni*, *Mycoplasma pneumoniae*, cytomegalovirus, herpes simplex virus, varicella zoster virus, Epstein-Barr virus, hepatitis A virus, hepatitis B and E, the human immunodeficiency virus (HIV), dengue, chikungunya and ZIKA viruses (Rodriguez et al. [@CR49]). During the ZIKA virus epidemic (2016--2018), several studies reported the development of GBS among ZIKA infected patients, including children. The individuals who developed GBS after ZIKA virus infection had poor prognoses compared to the general population (Araujo et al. [@CR3]; Arias et al. [@CR5]; Barbi et al. [@CR9]; Dirlikov et al. [@CR22]; Major et al. [@CR42]). A recent case report described the potential of SARS-CoV-2 infection which resulted in the detection of reversible GBS (Zhao et al. [@CR58]). A 61-year-old woman with a travel history to Wuhan, China during the 3rd week of January 2020 was first asymptomatic for COVID-19 infection, but developed symptoms of GBS. Subsequently, during follow up treatment, she developed dry cough and fever when SARS-CoV-2 infection was confirmed. The patient was treated with Arbidol and boosted Lopinavir with Ritonavir. With treatment the patient clinical status returned to normal (Zhao et al. [@CR58]). In prior reports, GBS was observed in four patients within a cohort of 23 with confirmed MERS CoV (Kim et al. [@CR34]). Strikingly, the peripheral neurological complications develop after 2 to 3 weeks of recovery from respiratory illness (Kim et al. [@CR34]). Although no direct correlation was established between the development of GBS and COVID-19 for this particular case, the incidence warrants follow up by performing an epidemiological study to monitor development of GBS and or associated neurological disorders among acute/chronic COVID-19 patients as well as in patients who successfully recover from the disease.

Therapeutics for COVID-19 Neurological Manifestations {#Sec6}
=====================================================

The COVID-19 patients, who are above 60 years of age with comorbid conditions that include type 2 diabetes, hypertension, hyperlipidemia and chronic obstructive pulmonary disease may have elevated levels of serum D-dimer, that may lead to embolic vascular events (Chen et al. [@CR13]; Mao et al. [@CR43]). This includes ischemic stroke necessitating treatment with anti-coagulants (Jin et al. [@CR32]; Khosravani et al. [@CR33]). Hypertensive patients with SARS-CoV-2 infection may have fluctuations in blood pressure that may lead to intracranial hemorrhage. In these patients, to control hypertension, ACE inhibitors should be replaced with calcium channel blockers or diuretics. Cerebrospinal fluid (CSF) should be tested by quantitative polymerase chain reaction tests to detect SARS-CoV-2 in patients with suspected intra-cranial infection. During this COVID-19 pandemic period, all patients coming to the emergency room should be evaluated for symptoms that overlap with neurological manifestations. Individuals suffering from an opioid use disorder are likely at higher risk of developing severe disease. All together the significant neurological disease manifestations now known warrant additional detailed study to explore the diagnostics, disease mechanisms and therapeutic options of COVID-19 disease.
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